Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury

  • With its targeted multimodal approach, NeuroAiD™II offers a broad range of therapeutic benefits to TBI patients.
  • NeuroAiD™II was well-tolerated by TBI patients with a favourable safety profile.

SINGAPORE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Moleac announced promising results from the SAMURAI double-blind study in patients with mild traumatic brain injury (mTBI) receiving a 6-month course of NeuroAiD™II. In the study, the NeuroAiD™II group showed significant improvement in their post-concussion symptoms, quality of life and mood, compared to those in the placebo group.   

Presented by Professor Valery Feigin at the World Congress of Neurology, last October in Montreal, these results expand the list of therapeutic benefits of NeuroAiD™II observed in previous clinical trials conducted on TBI patients, and confirm its favourable safety profile1, 2, 3.

In the SAMURAI study, mTBI patients underwent a series of tests assessing various types of impairments and their recovery over time. For cognition, a self-assessment was done by the patient using a computerized scale, the Computerized Neurocognitive Assessment-Vital Signs (CNS-VS). For post-concussion symptoms, quality of life and mood, the tests were conducted by the investigators using 3 different scales: the Rivermead Post-Concussion Symptoms Questionnaire (RPQ), the Quality of Life after Brain Injury (QOLIBRI) scale, and the Hospital Anxiety and Depression Scale (HADS) respectively.

While the improvement of CNS-VS self-assessment score was not different between groups at the 6-month and 9-month time points with a surprising improvement in the placebo group, the assessments performed by investigators showed highly statistically significant benefits of NeuroAiD™II over placebo at both 6-month and 9-month time point, and on the 3 scales. These positive results reflect the durable benefits provided by NeuroAiD™II, even after treatment discontinuation.

“Persistent symptoms following a TBI can severely affect a patient’s day-to-day life. Following the pilot study BRAINS1, we are further encouraged by SAMURAI, illustrating the wide spectrum of benefits provided by NeuroAiD™II in helping patients to achieve a holistic recovery in the physical, cognitive and emotional aspects,” said David Picard, CEO of Moleac.

Professor Feigin added, “The trial showed that although NeuroAid did not significantly improved cognitive functioning in post mild traumatic brain injury individuals, it significantly reduced various other complaints associated with the injury (lightheadedness, headaches, dizziness, anxiety, depression etc) and improved overall health-related quality of life after mTBI. I have no doubts that, when indicated, millions of individuals with mTBI could benefit from using NeuroAid to alleviate their post-injury symptoms.”

TBI is an injury caused by a mechanical impact on the brain or skull or by the penetration of objects into the skull. Damage and death of brain cells often lead to neurological and cognitive deficits. The global incidence of TBI is about 50 to 60 million new events each year, with mTBI representing more than 90% of all TBI4. After one year, 20% to over 30% of mTBI patients continue to experience clinically significant sequelae and over 80% remain symptomatic5. Persistent deficits can highly affect one’s ability to live independently5. Moreover, these physical, cognitive, and emotional symptoms may persist for a long time6,7. This represents an urgent need for TBI treatment to not only treat physical symptoms but to positively impact the psychological and emotional well-being of the patients.

Dr. Sylvain Durrleman, Head of Medical Affairs at Moleac, commented, “Recovery from TBI is complex and multidimensional. With its multimodal mechanism of action, NeuroAiD™II is well-suited for TBI recovery, showing positive clinical impacts on physical symptoms and important parameters of the quality of life.”

On how the results may contribute to clinical practice in the disease area, Dr. Durrleman added, “We hope the results are meaningful to both healthcare practitionners and patients, further demonstrating the benefit of NeuroAiD™II in promoting recovery processes.”

For more information, please visit www.neuroaid.com.

About NeuroAiD™II

NeuroAiD™II is a scientifically-researched formulation containing 9 natural herbal ingredients, recommended for patients with established deficits to boost their recovery after a traumatic brain injury.

About Moleac

Moleac is a biopharmaceutical company committed to helping patients and families reconnect with their lives. Headquartered in Singapore, we are dedicated to developing scientifically proven innovative formulations that bridge therapeutic gaps and address unmet needs of patients with neurological conditions such as stroke, traumatic brain injuries and dementia.

Moleac’s flagship product NeuroAiD™II benefits more than 40,000 patients in over 35 countries every year.

For more information, please visit www.moleac.com.

Contact Details

Name of Press Contact: Clement Dif

Phone: +65 6211 3710

Email: communication@moleac.com

 


Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury

THỦ THUẬT HAY

Hướng dẫn chặn quảng cáo trên Facebook đơn giản hiệu quả

Facebook hiện giờ rất nhiều quảng cáo và bán hàng online, chắc hẳn các bạn đều sẽ cảm thấy rất phiền phức khi Facebook của mình xuất hiện nhan nhản những quảng cáo, livestream. Vậy bây giờ Trang Công Nghệ sẽ hướng dẫn

Khắc phục nhanh khi bị đổ nước hay chất lỏng vào máy tính

Bạn làm đổ một ly nước vào chiếc laptop yêu quý của mình? Bạn có thói quen đặt ly nước cạnh máy tính của bạn khi bạn đang làm việc hay sử dụng máy tính để chơi nhạc trong một bữa tiệc nào đó. Dù bạn cẩn thận tới mức nào

Hướng dẫn sử dụng Firefox Send để gửi tập tin qua mạng

Firefox Send là một trang chia sẻ tập tin miễn phí của Mozilla giúp chia sẻ tập tin lên đến 1 GB, mã hóa, tự động hết hạn sau 24h, chỉ cho phép tải về một lần.

Emerald Launcher - Trình khởi chạy siêu nhẹ dành cho những thiết bị Android cấu hình thấp

Cụ thể hơn, Emerald Launcher là trình khởi chạy siêu nhẹ được xây dựng dựa trên một mã nguồn mở từ lập trình viên Henri Dellal

ĐÁNH GIÁ NHANH

Baic Q7: Ngoài giá bán, còn gì khác để thuyết phục khách hàng Việt Nam

Với mức giá niêm yết 658 triệu (tặng 100% phí trước bạ), BAIC Q7 là một lựa chọn tương đối hấp dẫn trong phân khúc CUV 5 chỗ. Tuy nhiên, ngoài giá bán thì chiếc xe này có gì khác để thuyết phục khách hàng Việt Nam, vốn

Trên tay OPPO R11s: 6,01-inch tỷ lệ 18:9, camera 20MP, công nghệ AI, pin 3205mAh

Sau khi phát hành của OPPO R11 tháng Sáu năm ngoái, OEM Trung Quốc đã công bố người kế nhiệm tiếp theo là OPPO R11s. Chiếc điện thoại mới của hãng đi theo xu hướng màn hình vô cực, bezels mỏng và đang bắt đầu được bán